[Clinical use of ceftizoxime suppositories in pediatric infection].
Ceftizoxime suppositories (CZX-S) were given to 5 children comprising 3 with acute bronchitis, 1 with acute bronchitis complicated by enteritis, and 1 with acute urinary tract infection, in doses of 12.5 12.5-17.4 mg/kg with 1 suppository containing 125 mg or 250 mg (potency) given 3 times a day. The clinical response was "markedly effective" in 2 and "effective" in 3. Microbiologically CZX-S caused a eradication of 1 strain each of S. aureus and E. coli and caused a decrease of organisms in 1 strain of S. aureus. There were no adverse reactions or abnormal laboratory test findings attributable to CZX-S. In conclusion, CZX-S proved to be a clinically useful antibiotic preparation for the treatment of infection in children not suited to treatment with oral or intravenous preparations.
D001419:Bacteria / Q000187:drug effects; D001424:Bacterial Infections / Q000188:drug therapy*; D001991:Bronchitis / Q000188:drug therapy; D002439:Cefotaxime / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use; D015296:Ceftizoxime; D002675:Child, Preschool; D004341:Drug Evaluation; D004352:Drug Resistance, Microbial; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D013488:Suppositories; D014552:Urinary Tract Infections / Q000188:drug therapy
D013488:Suppositories; D015296:Ceftizoxime; D002439:Cefotaxime